TMS Co

TMS Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of TMS Co (4891.T) as of Nov 4, 2026 is 91.06 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 79.42 % — a change of 14.66% (higher).

FCF Conversion

91.06 %

YoY

14.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of TMS Co is 2026 91.06 % . FCF Conversion Rate (FCF/EBITDA) of TMS Co was 2025 79.42 % . It decreases by 14.66% higher compared to the previous year.

The TMS Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
102.13 JPY
Jan 1, 2022
116.35 JPY
Jan 1, 2023
81.56 JPY
Jan 1, 2024
86.06 JPY
Jan 1, 2025
79.42 JPY
Jan 1, 2026
91.06 JPY
The TMS Co FCF Conversion history
YEARFCF ConversionYoY
91.06 %+14.66%
79.42 %-7.71%
86.06 %+5.52%
81.56 %-29.90%
116.35 %+13.92%
102.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

FCF Conversion Rate (FCF/EBITDA) of TMS Co is 91.06 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of TMS Co changed from 79.42 % to 91.06 %, representing a 14.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) TMS Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s TMS Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — TMS Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — TMS Co